Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 389 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma, Open-angle Clear all
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

NCT00047515
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the United States, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 3, 2026, 2:13 PM EDT
Recruiting Not applicable Interventional

A Trial of Hydrus Microstent Versus Goniotomy

NCT06289491
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle
Interventions
Hydrus Microstent, Incisional goniotomy, Excisional goniotomy
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 3, 2026, 2:13 PM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 3, 2026, 2:13 PM EDT
Terminated No phase listed Observational

Development and Validation of a Model to Predict Fast Progression in Glaucoma

NCT04454190
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions
Collection of genetic material
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
1,152 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03657797
View directory record Official record
Conditions
Glaucoma, Open-Angle, Hypertension, Ocular
Interventions
NCX 470, Latanoprost 0.005%
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Xalatan, Travatan Z
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
5
States / cities
East Meadow, New York • Lynbrook, New York • Rockville Centre, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Sep 3, 2026, 2:13 PM EDT
Completed No phase listed Observational

Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure

NCT01779778
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 3, 2026, 2:13 PM EDT
Not listed Not applicable Interventional

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

NCT01841450
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
iStent, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
14
States / cities
Irvine, California • Montebello, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 3, 2026, 2:13 PM EDT
Recruiting No phase listed Observational

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

NCT07076303
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Direct Selective Laser Trabuloplasty
Device
Lead sponsor
Brian Shafer
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2026
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 3, 2026, 2:13 PM EDT
Completed No phase listed Observational Results available

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

NCT01836042
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00465621
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Xalatan
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Sep 3, 2026, 2:13 PM EDT
Active, not recruiting No phase listed Observational

Advanced Glaucoma Progression Study

NCT01742819
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 3, 2026, 2:13 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

NCT02507687
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 3, 2026, 2:13 PM EDT
Completed No phase listed Observational

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

NCT04647214
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Culver City, California • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 3, 2026, 2:13 PM EDT
Recruiting Not applicable Interventional

Direct vs Standard SLT for Glaucoma: A Noninferiority Trial

NCT07408154
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions
Direct Selective laser Trabeculoplasty
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Not applicable Interventional

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 2:13 PM EDT
Terminated No phase listed Observational

Effect of Xen Implantation on the Aqueous Humor Proteome

NCT04141865
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Xen, Aqueous shunt
Device
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 3, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 3, 2026, 2:13 PM EDT